ARTHEx also has ATX-01 in preclinical testing for myotonic dystrophy type 2 (DM2). “Although DM2 is caused by a different mutation, it similarly results in the sequestration of MBNL proteins ...

The comic's widow, Dara Gottfried, says a portion of sales of 'Still Screaming' will benefit the Gilbert Gottfried Myotonic ...

We also investigate the pathogenic mechanisms of myotonic dystrophy, type 1 (DM1), an autosomal dominant neuromuscular disorder affecting multiple tissues including muscle, heart and the central ...

It usually affects small muscles first, such as those in the: The type of myotonic dystrophy that begins at birth is more serious. Other forms get worse very slowly, and can take 50 or 60 years to ...

The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic dystrophy type 1 ... the ongoing phase 1/2 ACHIEVE global clinical ...

Dyne Therapeutics (NASDAQ:DYN) reported clinical data from its ongoing Phase 1/2 trial of DYNE-101 in patients with myotonic dystrophy type 1.Shares down about 22% in early trade. DYNE-101 ...

has granted Fast Track designation for DYNE-101 for the treatment of myotonic dystrophy type 1 (DM1). DYNE-101 is currently being evaluated in the ongoing Phase 1/2 ACHIEVE global clinical trial.